Ketoreductase mutant as well as gene, recombinant plasmid, engineering bacterium and application of ketoreductase mutant in preparation of ethyl hydroxide

By designing ketoreductase mutants with enhanced tolerance and combining substrates for catalysis, the problem of low enzymatic conversion efficiency in the existing technology is solved, efficient production of ethyl hydroxyl compounds is achieved, and production efficiency and environmental protection are improved. .

CN118995651APending Publication Date: 2024-11-22HUNAN NORCHEM PHARMACEUTICAL CO LTD

Patent Information

Application Number
CN202411476317.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-22
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the prior art, when preparing chiral intermediate ethyl hydroxyl of levonorgestrel, the enzymatic method has problems such as low conversion efficiency, low production efficiency, strict environment, and difficult wastewater treatment, especially the tolerance of ketone reductase. Inadequate sexuality leads to substrate insolubleness and enzyme inactivation.

Method used

A ketoreductase mutant was designed to screen enzymes that tolerate high concentrations of isopropanol and high temperatures through site-directed saturation mutations of amino acid sequences, and combined with substrates for catalysis. BL21DE3 competent cells were used as hosts to construct recombinant plasmids and perform Grow and induce culture, use phosphate buffer and isopropanol for reduction reactions, optimize conditions to improve conversion efficiency.

Benefits of technology

The high-efficiency ketone reduction of the ethyl condensate was achieved, the substrate dosage concentration was increased to 10%, the conversion time was ≤24h, the ee value was ≥99.0%, the production efficiency was high, environmentally friendly and impurity-free.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995651A_ABST
    Figure CN118995651A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of bioengineering, and discloses a ketoreductase mutant as well as a gene, a recombinant plasmid, an engineering bacterium and application of the ketoreductase mutant in preparation of ethyl hydroxide. The ketoreductase mutant disclosed by the invention is obtained by performing site-directed saturation mutation on amino acid key sites combined with a substrate and then performing screening, and the ketoreductase mutant is high in thallus activity, so that the dosage concentration of the substrate is increased to 10%, the conversion time is less than or equal to 24 hours, and the ee value is greater than or equal to 99.0%; therefore, the production of the ketone reduction product ethyl hydroxide of the ethyl condensate is more efficient and environment-friendly. According to the method, the ethyl hydroxide is prepared by adopting the gene for coding the ketoreductase or the ketoreductase mutant, the operation is simple, the production efficiency is high, the conversion rate is high, the yield is high, and basically no other impurities are generated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of bioengineering, and particularly relates to a ketoreductase mutant and its gene, recombinant plasmid, engineering bacteria, and application in preparing ethyl hydroxylate, a chiral intermediate of levonorgestrel. Background Art

[0002] Levonorgestrel is a commonly used and widely used female emergency contraceptive. Its synthesis pathway is as follows Figure 1 As shown, ethyl hydroxylate is an important chiral intermediate of levonorgestrel. The process of preparing it by chemical method is very difficult and the yield is low. For a long time, the endogenous ketoreductase in yeast is mainly used to catalyze the low concentration of ethyl condensate in the form of whole cells to prepare ethyl hydroxylate. In recent years, the enzymatic method has gradually become an important solution for synthesizing related chiral compounds. There are also related reports on the replacement of the whole cell method by the enzymatic method, but both have certain application limitations.

[0003] Chinese patent document CN201711303967.7 reported that after whole cells were obtained by fermentation with baker's yeast, 0.8% ethyl condensate was added and the conversion was continued for 72 hours to obtain ethyl hydroxylate. The fermentation process requires aseptic operation, which is harsh on the environment. In addition, the low conversion concentration and long conversion time result in very low production efficiency. As the fermentation cycle is extended, the ethyl hydroxylate will be degraded to a certain extent, thereby affecting the yield.

[0004] Chinese patent document CN202011178327.X reported the use of a ketoreductase mutant strain TbADH and the function of its own isopropanol dehydrogenase to carry out NADP+ cyclic conversion to obtain ethyl hydroxylate. However, due to the low solubility of the substrate ethyl condensate, the addition of 5-15% final concentration of isopropanol during the conversion process cannot effectively dissolve the substrate. The conversion process has been in a two-phase conversion of solid and liquid phases. The insolubility of the substrate leads to low enzyme conversion efficiency and a longer actual production conversion cycle. However, when the isopropanol concentration is continued to be increased to increase the substrate solubility, most ketoreductases cannot tolerate high concentrations of isopropanol and cause enzyme inactivation.

[0005] Chinese patent document CN202210591486.5 reported the use of a ketoreductase in combination with glucose dehydrogenase to carry out NADP+ cyclic conversion to obtain ethyl hydroxylate, but in the process, surfactants such as Tween 60, Triton X-100, and defoaming agent were used to dissolve the ethyl condensate and then react. The ethyl condensate could not be effectively dissolved, and a large amount of surfactants could only play a dissolving role. During the conversion process, the pH needs to be controlled in real time to maintain specific conditions, and the converted surfactant cannot be recycled, making the subsequent treatment of the wastewater very difficult. Summary of the invention

[0006] The technical problem to be solved by the present invention is to overcome the deficiencies and defects mentioned in the above background technology and provide a ketoreductase mutant and its gene, recombinant plasmid, engineered bacteria, and application in the preparation of the chiral intermediate ethyl hydroxylate of levonorgestrel.

[0007] In order to solve the above technical problems, the technical solution proposed by the present invention is: In a first aspect, the present invention provides a ketoreductase mutant, whose amino acid sequence is shown in SEQ ID NO.4.

[0008] In a second aspect, the present invention provides a gene encoding a ketoreductase mutant, the nucleotide sequence of which is shown in SEQ ID NO.3.

[0009] In a third aspect, the present invention provides a recombinant plasmid comprising a gene with a nucleotide sequence as shown in SEQ ID NO.3.

[0010] In a fourth aspect, the present invention provides an engineered bacterium, which is obtained by taking BL21DE3 competent cells as hosts and transferring the recombinant plasmid into the host cells.

[0011] In a fifth aspect, the present invention provides an application of a gene encoding a ketoreductase or a ketoreductase mutant in the preparation of ethyl hydroxylate, wherein the gene sequence encoding the ketoreductase is shown in SEQ ID NO.1, and the gene sequence encoding the ketoreductase mutant is shown in SEQ ID NO.3.

[0012] In a sixth aspect, the present invention provides a method for preparing a chiral intermediate ethyl hydroxylate of levonorgestrel, comprising the following steps: growing and inducing the engineered bacteria, collecting the wet bacteria and performing ultrasonic crushing to obtain a crude enzyme solution; using an ethyl condensate as a substrate, performing a reduction reaction with the crude enzyme solution and isopropanol, and the obtained product is the ethyl hydroxylate.

[0013] In the above preparation method, preferably, the construction method of the engineering bacteria is as follows: (1) constructing a gene encoding ketoreductase or a ketoreductase mutant into a plasmid expression vector to obtain a recombinant plasmid; the gene sequence encoding the ketoreductase is shown in SEQ ID NO.1, and the gene sequence encoding the ketoreductase mutant is shown in SEQ ID NO.3; (2) The recombinant plasmid is transferred into BL21DE3 competent cells to obtain engineered bacteria.

[0014] More preferably, the plasmid expression vector is pET-28a.

[0015] Preferably, the growth medium used in the growth culture is LB medium, and the culture conditions are: 36-38°C for 4-6 hours; the induction medium used in the induction culture is isopropyl-β-D-thiogalactoside, and the culture conditions are: 16-28°C for 16-24 hours; After collecting wet bacteria, the volume is fixed with buffer, and then dispersed and ultrasonically broken in an ice bath to obtain a crude enzyme solution; the buffer is a phosphate buffer with a concentration of 0.01-0.5M and a pH value of 6.5-8.5; the concentration of the bacteria after adding the buffer is 200g / L.

[0016] Preferably, the specific operation of the reduction reaction is as follows: add the ethyl condensate to isopropanol, heat it (to 35-55°C) and stir to dissolve it, add phosphate buffer, and then add NADP + The reaction mixture is stirred to a final concentration of 0.2-0.3 g / L, dissolved by stirring, and the crude enzyme solution is added. The reaction is carried out at 35-55° C. and 150-200 rpm. The conversion is monitored by TLC. The reaction is terminated after 8-28 hours. The isopropanol is removed by vacuum concentration. During the process, ice water is added for water precipitation. After the solvent is completely replaced, crystals are grown at 4-10° C., filtered and dried to obtain a conversion product. The dosage ratio of the isopropanol and the ethyl condensate is (20-50) mL: (5-6) g, and the volume ratio of the isopropanol and the phosphate buffer is (20-50): (50-80). The concentration of the phosphate buffer is 0.01-0.5 M, and the pH value is 6.5-8.5.

[0017] The enzyme conversion reaction principle of the present invention is as follows Figure 2 As shown. According to the characteristics that the melting point of the intermediate ethyl condensate of levonorgestrel is only 65°C and it can be completely dissolved in isopropanol, a ketoreductase that can tolerate high concentrations of isopropanol and high temperatures is selected as the enzyme property requirement. According to the similarity of the substrate structure, the target protein 4RF2-A that can catalyze the ethyl condensate is identified through computer homology alignment. This type of ketoreductase comes from Lentilactobacillus kefiri. The LkADH enzyme is a bifunctional enzyme. Although it has the activity of isopropanol dehydrogenase, there is still room for further improvement in activity.

[0018] Compared with the prior art, the present invention has the following beneficial effects: 1. The ketoreductase mutant of the present invention is obtained by performing site-directed saturation mutagenesis on the key amino acid sites that bind to the substrate and then screening. The bacterial cell activity of the ketoreductase mutant is high, so that the substrate dosage concentration is increased to 10%, the conversion time is ≤24h, and the ee value is ≥99.0%, thereby making the production of ethyl hydroxylate, the keto reduction product of the ethyl condensate, more efficient and environmentally friendly.

[0019] 2. The present invention uses a gene encoding ketoreductase or a ketoreductase mutant to prepare ethyl hydroxylate, which has simple operation, high production efficiency, high conversion rate, high yield, and basically no other impurities are generated. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0021] Figure 1 It is the synthetic pathway for levonorgestrel; Figure 2 It is the enzyme conversion reaction principle of the present invention; Figure 3 This is the TLC spot plate result of the original LkADH crude enzyme solution in Example 1; Figure 4 is the protein electrophoresis diagram of the crude enzyme solution of mutant LkADH-6 in Example 2; Figure 5 The TLC spot plate results of the original LkADH crude enzyme solution and the mutant LkADH-6 crude enzyme solution in Example 3 are compared; Figure 6 This is the liquid phase spectrum of the crude enzyme solution of mutant LkADH-6 in Example 3 converted into ethyl condensate. DETAILED DESCRIPTION

[0022] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively and meticulously below in conjunction with the accompanying drawings and preferred embodiments of the present invention, but the protection scope of the present invention is not limited to the following specific embodiments.

[0023] Unless otherwise defined, all professional terms used below have the same meanings as those generally understood by those skilled in the art. The professional terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of protection of the present invention.

[0024] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0025] The BL21(DE3) competent cells (BL21(DE3) Competent Cell) used in the present invention are derived from the Escherichia coli BL21(DE3) strain.

[0026] Embodiment 1: Application of LkADH ketoreductase in the preparation of chiral intermediate ethyl hydroxylate of levonorgestrel.

[0027] The present invention performs artificial full gene synthesis on the LkADH enzyme with high substrate-enzyme binding correlation, and prepares the corresponding LkADH crude enzyme solution. The actual enzyme reaction determines that the enzyme can convert the ethyl condensate into ethyl hydroxylate without generating other impurities. The specific application method is as follows: 1. Preparation of original LkADH crude enzyme solution 1) The nucleotide sequence of the artificially synthesized ketoreductase is SEQ ID NO.1, and the amino acid sequence is SEQ ID NO.2. SEQ ID NO.1 is constructed into the plasmid expression vector of pET-28a to obtain a recombinant plasmid; 2) The recombinant plasmid was transferred into the host cell BL21(DE3) to obtain the engineered strain; 3) Inoculate the engineered strain into LB medium, culture at 37°C for 6 h, add 0.1 mM IPTG (isopropyl-β-D-thiogalactoside), and culture at 28°C for 16 h; 4) After collecting the bacteria by centrifugation, the volume was fixed to 200 g / L with 0.1 M pH 8.0 phosphate buffer. After the bacteria were dispersed, they were ultrasonically disrupted in an ice bath to obtain LkADH crude enzyme solution.

[0028] 2. LkADH crude enzyme solution converted into ethyl condensate Add 40 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate and heat to 45 °C until it is completely dissolved. Then slowly add 50 mL of 0.1 M pH = 8.0 phosphate buffer and add NADP + To a final concentration of 0.2 g / L, stir to dissolve, add 10 mL of LkADH crude enzyme solution, react at 35 ° C and 180 rpm, monitor the conversion by TLC, terminate after 28 hours, and concentrate under vacuum at 60 ° C to remove isopropanol. During the process, slowly add 50 mL of ice water for water precipitation. After complete replacement of the solvent, grow the crystal at 4-10 ° C for 1 hour, filter and dry, and dry at 50 ° C to obtain the conversion product.

[0029] The TLC results of the conversion products are as follows: Figure 3 As shown. Figure 3 It can be seen that after 28 hours of conversion, the conversion rate is about 50%.

[0030] The sequence of SEQ ID NO.1 is as follows: atgaccgaccgactcaaaggtaaagttgctattgtaactgggggcactttgggtataggactggccatagcggacaagtttgttgaagaaggggctaaagttgttataaccggtagacacgcggacgtaggcgagaaggcggctaagtccataggtggaacggatgtgatccgtttcgtccagcatgacgcttccgatgaagcgggatggacaaagctgttcgatacaactgaggaggcattcggaccggtgacaacggtagtgaataatgcggggattgcagttagcaagtcggtagaggataccacgaccgaagagtggcgaaaacttcttagcgtaaatttggacggagtattcttcggtacgaggctgggaatccaacgcatgaagaataaaggtcttggggcctcgattatcaatatgtcctctattgaagggttcgtgggggatcccacattgggtgcctataatgcgtctaaaggcgctgtgaggataatgtcgaaatccgccgcattggactgcgcgcttaaggactatgacgttagggtaaatactgtgcaccccgggtacatcaaaacacctctagtagacgacttggagggtgcagaagaaatgatgtcacaacgtaccaagaccccgatgggacacataggggaacctaatgatattgcatggatatgtgtatacctagccagtgatgagagtaagtttgccaccggggcggagttcgtagtagacggtggatacacggcgcag。

[0031] The sequence of SEQ ID NO.2 is as follows: MTDRLKGKVAIVTGGTLGLAIADKFVEEGAKVVITGRHADVGEKAAKSIGGTDVIRFVQHDASDEAGWTKLFDTTEEAFGPVTTVVNNAGIAVSKSVEDTTTEEWRKLLSVNLDGVFFGTRLGI QRMKNKGLGASIINMSSIEGFVGDPTLGAYNASKGAVRIMSKSAALDCALKDYDVRVNTVHPGYIKTPLVDDLEGAEEMMSQRTKTPMGHIGEPNDIAWICVYLASDESKFATGAEFVVDGGYTAQ.

[0032] Embodiment 2: A LkADH ketoreductase mutant of the present invention is constructed as follows: according to the key binding sites 7, 17, 64, 93, 96, 100, 147, 152, 194, 216 of the enzyme and the substrate, a mutant primer is designed using the degenerate codon NNK, and pET28a-LKADH is used as a template. A high-fidelity polymerase Pfx is used to perform PCR to build a library mutation at each site, and the activity is measured. The primer sequences used are shown in Table 1 below.

[0033] Table 1: Primer sequences

[0034] Detection method of mutant enzyme activity: Use 50% DMSO aqueous solution to dissolve the ethyl condensate with a final concentration of 0.6 mM under ultrasonic conditions, dilute the crude enzyme solution 10-50 times and add 20 μL, make up to the volume of 250 μL with 0.1 M pH 8.5 phosphate buffer, incubate at 45°C for 10 min, then add 0.2 g / L final concentration of NADPH, use a microplate reader to detect the absorbance change of NADPH at 340 nm, the larger the downward slope, the higher the enzyme activity.

[0035] According to the saturation mutation results, a combination mutant of a single mutation site was constructed, and the obtained mutant was picked up into a test tube containing 4 mL of LB medium for culture. The activity of the expressed protein was detected. The activity detection results of the mutants are shown in Table 2. A mutant LkADH-6 with high product stereoselectivity and high activity was obtained, and its mutation sites were I93S, S96A, F147D and P194V, and its nucleotide sequence and amino acid sequence were SEQ ID NO.3 and SEQ ID NO.4, respectively.

[0036] Table 2: Viability test results of variants

[0037] The sequence of SEQ ID NO.3 is as follows: atgacagacagactcaaaggcaaagtcgctatcgtgaccggcggcacactagggattgggctagctatcgctgacaagtttgtggaagaaggagctaaggtggtaattaccggacgccacgcagatgtaggcgaaaaagctgcgaagagtataggtggtaccgatgttataaggttcgttcaacacgacgcgtcagacgaagcaggctggaccaagttattcgacacaacagaggaagcgttcggccccgtaacaacggtagtaaataacgcaggtagtgctgtcgccaagtcggtggaggatactacaacagaagaatggcgaaagttgctgtccgtgaatctagacggggtattctttggaactcggttggggatacaacggatgaagaacaaggggctaggggcttccattataaacatgtcatcaatagaaggagatgtcggcgatcctactctaggtgcctataacgctagtaaaggtgctgtacgaattatgtcgaagtcagctgcattagactgcgcccttaaggattacgatgtccgtgtgaatactgtccacccgggctacattaaaaccgtgctagtggatgaccttgagggcgcggaggagatgatgtctcaacgtactaagacccctatggggcatatcggagaacctaatgatatagcatggatctgcgtgtacctggcatcggacgagtccaaatttgcaaccggtgccgagtttgtggttgacgggggttacacggcgcag。

[0038] The sequence of SEQ ID NO.4 is as follows: MTDRLKGKVAIVTGGTLGIGLAIADKFVEEGAKVVITGRHADVGEKAAKSIGGTDVIRFVQHDASDEAGWTKLFDTTEEAFGPVTTVVNNAGSAVAKSVEDTTTEEWRKLLSVNLDGVFFGTRLGI QRMKNKGLGASIINMSSIEGDVGDPTLGAYNASKGAVRIMSKSAALDCALKDYDVRVNTVHPGYIKTVLVDDLEGAEEMMSQRTKTPMGHIGEPNDIAWICVYLASDESKFATGAEFVVDGGYTAQ.

[0039] Embodiment 3: The application of LkADH ketoreductase mutant LkADH-6 in the preparation of chiral intermediate ethyl hydroxylate of levonorgestrel is as follows: 1. Preparation of LkADH-6 crude enzyme solution 1) The gene with the sequence shown in SEQ ID NO.3 was constructed into the plasmid expression vector of pET-28a to obtain a recombinant plasmid; 2) The recombinant plasmid was transferred into the host cell BL21 (DE3) to obtain the LkADH-6 mutant engineered strain; 3) The LkADH-6 mutant engineered strain was inoculated into LB medium, cultured at 37°C for 4 h, 0.1 mM IPTG (isopropyl-β-D-thiogalactoside) was added, and cultured at 28°C for 16 h; 4) After collecting the bacteria by centrifugation, the volume was fixed to 200 g / L with 0.1 M pH 8.0 phosphate buffer. After the bacteria were dispersed, they were ultrasonically disrupted in an ice bath to obtain LkADH-6 crude enzyme solution.

[0040] The obtained crude LkADH-6 enzyme solution was subjected to protein electrophoresis, and Figure 4 It was observed that the proteins expressed by the LkADH-6 mutant engineering strain were all soluble, the molecular weight of the purified target protein was about 26.7kD, and the band position was consistent with the protein electrophoresis results.

[0041] 2. Conversion of crude enzyme solution of LkADH-6 into ethyl condensate Add 40 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate and heat to 45 °C until it is completely dissolved. Then slowly add 50 mL of 0.1 M pH = 8.0 phosphate buffer and add NADP +To a final concentration of 0.2 g / L, stir to dissolve, add 10 mL of LkADH-6 crude enzyme solution, monitor the conversion by TLC at 35 ° C and 180 rpm, terminate the reaction after 28 hours, concentrate under vacuum at 60 ° C to remove isopropanol, slowly add 50 mL of ice water for water precipitation during the process, and after complete replacement of the solvent, grow the crystal at 4-10 ° C for 1 hour, filter and dry, and dry at 50 ° C to obtain the conversion product.

[0042] The TLC results of the conversion solution are as follows Figure 5 As shown. Figure 5 It can be seen that after 28 hours, there is basically no substrate residue monitored by TLC.

[0043] The liquid phase spectrum of LkADH-6 crude enzyme solution conversion is as follows Figure 6 As shown, the liquid phase showed that the substrate residue was only 0.77% and the product was 99.0%.

[0044] The crude enzyme solution of LkADH-6 was subjected to enzyme conversion under different conditions, and the following experiments were performed respectively: (1) Add 40 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate, heat and stir to dissolve. Add 50 mL of phosphate buffer (pH = 8.0, 0.1 M), keep the temperature at 35 ° C and stir, add 10 mL of crude enzyme solution, and add NADP + 0.2g / L, monitor the conversion by TLC, react for 12h, TLC detects the conversion rate of 99%, remove isopropanol by vacuum decompression at 60℃, crystallize at 10℃, collect powder in the aqueous phase, filter and dry. The calculated weight yield is 98.2%.

[0045] (2) Add 40 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate, heat and stir to dissolve. Add 50 mL of phosphate buffer (pH = 8.0, 0.1 M), keep the temperature at 45 ° C and stir, add 10 mL of crude enzyme solution, and add NADP + 0.2g / L, monitor the conversion by TLC, react for 10h, TLC detects the conversion rate of 99%, remove isopropanol by vacuum reduction at 60℃, crystallize at 10℃, collect powder in the aqueous phase, filter and dry. The calculated weight yield is 99.1%.

[0046] (3) Add 40 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate to dissolve, and stir at 45°C. Add 50 mL of phosphate buffer (pH = 8.5, 0.1 M), and add NADP + 0.2g / L, stir until dissolved, add 10mL of crude enzyme solution, monitor conversion by TLC, react for 10h, TLC detection conversion rate is 99%, remove isopropanol under vacuum at 60℃, crystallize at 10℃, collect powder in water phase, filter and dry. Calculate weight yield is 97.8%.

[0047] (4) Add 40 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate to dissolve, and stir at 45 °C. Add 50 mL of buffer (pH = 6.5, 0.1 M), and add NADP + 0.2g / L, stir until dissolved, add 10mL of crude enzyme solution, monitor conversion by TLC, react for 16h, TLC detection conversion rate 99%, remove isopropanol under vacuum at 60℃, crystallize at 10℃, collect powder in water phase, filter and dry. Calculate weight yield 99.0%.

[0048] (5) Add 40 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate to dissolve, and stir at 45°C. Add 50 mL of phosphate buffer (pH = 7.5, 0.1 M), and add NADP + 0.2g / L, stirred until dissolved, added 10mL of crude enzyme solution, monitored conversion by TLC, reacted for 12h, TLC detected conversion rate of 99%, removed isopropanol under vacuum at 60℃, crystallized at 10℃, collected powder in aqueous phase, filtered and dried. Calculated weight yield of 98.6%.

[0049] (6) Add 50 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate to dissolve, and stir at 45°C. Add 40 mL of phosphate buffer (pH = 8.5, 0.1 M), and add NADP + 0.2g / L, stir until dissolved, add 10mL of crude enzyme solution, monitor conversion by TLC, react for 8h, TLC detection conversion rate is 99%, remove isopropanol under vacuum at 60℃, crystallize at 10℃, collect powder in water phase, filter and dry. Calculate weight yield is 99.5%.

[0050] (7) Add 30 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate to dissolve, and stir at 45°C. Add 60 mL of phosphate buffer (pH = 8.5, 0.1 M), and add NADP + 0.2g / L, stir until dissolved, add 10mL of crude enzyme solution, monitor conversion by TLC, react for 12h, TLC detection conversion rate 99%, remove isopropanol under vacuum at 60℃, crystallize at 10℃, collect powder in water phase, filter and dry. Calculate weight yield 99.5%.

[0051] (8) Add 50 mL of isopropanol to the conversion bottle, then add 5 g of ethyl condensate to dissolve, and stir while maintaining the temperature at 45°C. Add 45 mL of phosphate buffer (pH = 8.5, 0.1 M), and add NADP + 0.2g / L, stirred until dissolved, added 5mL of crude enzyme solution, monitored conversion by TLC, reacted for 8h, TLC detected conversion rate of 99%, removed isopropanol under vacuum at 60℃, crystallized at 10℃, collected powder in aqueous phase, filtered and dried. Calculated weight yield of 99.5%.

[0052] (9) Add 50 mL of isopropanol to the conversion bottle, then add 7 g of ethyl condensate to dissolve, and stir at 45°C. Add 40 mL of phosphate buffer (pH = 8.5, 0.1 M), and add NADP + 0.2g / L, stir until dissolved, add 5mL of crude enzyme solution, monitor conversion by TLC, react for 10h, TLC detection conversion rate is 99%, remove isopropanol under vacuum at 60℃, crystallize at 10℃, collect powder in water phase, filter and dry. Calculate weight yield is 98.5%.

[0053] The above experiments show that the ethyl condensates obtained at different isopropanol concentrations, different bacterial dosages, different pH values, and different temperatures all have good substrate conversion rates, and the activity is improved to a certain extent, especially at pH = 8.5, 50% isopropanol (volume ratio), and temperature 45°C. During the conversion process, the mutant LkADH-6 can convert the substrate ethyl condensate most quickly.

[0054] In summary, the present invention utilizes the decrease in light absorption of the coenzyme NADPH during the conversion process of the enzyme as a high-throughput screening method, performs site-directed saturation mutation and combined mutation on the key amino acid sites binding to the substrate, and screens out a ketoreductase mutant LkADH-6 with a 2.3-fold increase in bacterial viability, so that the substrate dosage concentration is increased to 10%, the conversion time is ≤24h, and the ee value is ≥99.0%, thereby making the production of ethyl hydroxylate, the ketone reduction product of the ethyl condensate, more efficient and environmentally friendly.

Claims

1. A ketoreductase mutant, characterized in that: Its amino acid sequence is shown in SEQ ID NO.

4.

2. A gene encoding a ketoreductase mutant, characterized in that: Its nucleotide sequence is shown in SEQ ID NO.

3.

3. A recombinant plasmid, characterized in that: It comprises the gene according to claim 3.

4. An engineered bacterium, characterized in that: The recombinant plasmid as claimed in claim 3 is introduced into BL21DE3 competent cells as hosts to obtain the recombinant plasmid.

5. Use of a gene encoding ketoreductase or a ketoreductase mutant in the preparation of ethyl hydroxylate, characterized in that: The gene sequence encoding the ketoreductase is shown in SEQ ID NO.1, and the gene sequence encoding the ketoreductase mutant is shown in SEQ ID NO.

3.

6. A method for preparing ethyl hydroxylate, characterized in that: The method comprises the following steps: growing and inducing the engineered bacteria as claimed in claim 4, collecting the wet bacteria and performing ultrasonic crushing to obtain a crude enzyme solution; using an ethyl condensate as a substrate, performing a reduction reaction with the crude enzyme solution and isopropanol, and the obtained product is the ethyl hydroxylate.

7. The preparation method according to claim 6, characterized in that: The construction method of the engineering bacteria is as follows: (1) constructing a gene encoding ketoreductase or a ketoreductase mutant into a plasmid expression vector to obtain a recombinant plasmid; the gene sequence encoding the ketoreductase is shown in SEQ ID NO.1, and the gene sequence encoding the ketoreductase mutant is shown in SEQ ID NO.3; (2) The recombinant plasmid is transferred into BL21DE3 competent cells to obtain engineered bacteria.

8. The preparation method according to claim 7, characterized in that: The plasmid expression vector is pET-28a.

9. The preparation method according to claim 6, characterized in that: The growth culture medium used is LB medium, and the culture conditions are: 36-38°C for 4-6 hours; the induction culture medium used is isopropyl-β-D-thiogalactoside, and the culture conditions are: 16-28°C for 16-24 hours; After collecting wet bacteria, the volume is fixed with buffer, and then dispersed and ultrasonically broken in an ice bath to obtain a crude enzyme solution; the buffer is a phosphate buffer with a concentration of 0.01-0.5M and a pH value of 6.5-8.5; the concentration of the bacteria after adding the buffer is 200g / L.

10. The preparation method according to any one of claims 6 to 9, characterized in that: The specific operation of the reduction reaction is as follows: add ethyl condensate to isopropanol, heat and stir to dissolve it, add phosphate buffer, and then add NADP + The reaction mixture is stirred to a final concentration of 0.2-0.3 g / L, dissolved by stirring, and the crude enzyme solution is added. The reaction is carried out at 35-55° C. and 150-200 rpm. The conversion is monitored by TLC. The reaction is terminated after 8-28 hours. The isopropanol is removed by vacuum concentration. During the process, ice water is added for water precipitation. After the solvent is completely replaced, crystals are grown at 4-10° C., filtered and dried to obtain a conversion product. The dosage ratio of the isopropanol and the ethyl condensate is (20-50) mL: (5-6) g, and the volume ratio of the isopropanol and the phosphate buffer is (20-50): (50-80). The concentration of the phosphate buffer is 0.01-0.5 M, and the pH value is 6.5-8.5.

Citation Information

Patent Citations

  • A method of producing an ethyl hydroxide through biological fermentation

    CN107828828A

  • Carbonyl reductase mutant and application thereof

    CN111996176A

  • Enzymatic synthesis system of levonorgestrel intermediate and application

    CN115851843A

Cited By

  • Ketoreductase and application thereof in biosynthesis of phenylephrine hydrochloride

    CN119662576A

  • Totally-synthesized ketoreductase and application thereof

    CN120519414A

  • A fully synthetic ketoreductase enzyme and uses thereof

    CN120519414B